Basilea has announced an extension to its licence agreement with Pfizer (PFE) for Cresemba (for invasive fungal infections). The original deal granted PFE exclusive commercialisation rights to the product in Europe (ex-Nordics), Russia, Turkey and Israel and the new amendment includes China and 16 countries within Asia Pacific. The extension of Cresemba’s global footprint at this stage highlights PFE’s commitment to the product in areas outside of Europe. Concomitantly Basilea has
07 Dec 2017
Pfizer Cresemba deal extended to Asia and China
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pfizer Cresemba deal extended to Asia and China
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
07 Dec 2017 -
Author:
Dr Susie Jana -
Pages:
3
Basilea has announced an extension to its licence agreement with Pfizer (PFE) for Cresemba (for invasive fungal infections). The original deal granted PFE exclusive commercialisation rights to the product in Europe (ex-Nordics), Russia, Turkey and Israel and the new amendment includes China and 16 countries within Asia Pacific. The extension of Cresemba’s global footprint at this stage highlights PFE’s commitment to the product in areas outside of Europe. Concomitantly Basilea has